WB result of SAMD9 Recombinant Rabbit mAb
Primary antibody: SAMD9 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: Raji whole cell lysate 20 μg
Lane 2: MCF7 whole cell lysate 20 μg
Lane 3: A-431 whole cell lysate 20 μg
Lane 4: BxPC-3 whole cell lysate 20 μg
Lane 5: SK-OV-3 whole cell lysate 20 μg
Lane 6: HeLa whole cell lysate 20 μg
Negative control: Raji whole cell lysate; MCF7 whole cell lysate
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 185 kDa
Observed MW: 185 kDa
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | SAMD9 |
| Synonyms | Sterile alpha motif domain-containing protein 9; C7orf5; DRIF1; KIAA2004; OEF1 |
| Immunogen | Recombinant Protein |
| Location | Cytoplasm |
| Accession | Q5K651 |
| Clone Number | S-4324-1 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu |
| Positive Sample | A-431, BxPC-3, SK-OV-3, HeLa |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu |
Background
SAMD9 (sterile alpha motif domain-containing protein 9) is a widely expressed cytoplasmic multidomain protein that combines antiviral defense, translational repression, and regulation of cell proliferation. Through its effector domain, it preferentially binds double-stranded nucleic acids and specifically cleaves phenylalanine tRNA, thereby suppressing global protein translation, while also playing a key role in antiviral granule formation and innate immune responses. SAMD9 expression is induced by interferon and TNF-α, and upon activation it downregulates MYC and E2F target genes, thereby inhibiting cell proliferation. Structurally, SAMD9 exists predominantly in a closed, autoinhibited conformation stabilized by an ATP-bound NOD module and extensive intramolecular interactions; pathogenic gain-of-function mutations disrupt these autoinhibitory interfaces, leading to aberrant protein activation. Clinically, biallelic loss-of-function mutations in SAMD9 cause normophosphatemic familial tumoral calcinosis, whereas heterozygous gain-of-function mutations cause MIRAGE syndrome (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy) and predispose to monosomy 7 myelodysplastic syndrome and leukemia.
Picture
Picture
Western Blot
